Navigation Links
Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
Date:1/17/2013

t www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval fo
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
2. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
5. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
6. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
7. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
8. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
9. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
10. Breast cancer cells growing in 3D-matrix revert to normal
11. First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... /PRNewswire/ - DNA Genotek, a leading provider of ... announced that The Anthony Nolan Trust, the UK,s largest ... a pilot project aimed at increasing donor recruitment. Bone ... HLA DNA testing to match leukemia patients with prospective ...
... ... leading technology services firm specializing in the intelligent integration of eCommerce, CRM and business ... to build an eCommerce system that will leverage its five divisions: Training, Field Services, ... ...
... CONVENTION, CHICAGO, Illinois , May 5, 2010 ... treatment for tuberculosis,(TB) will shortly start phase II clinical ... novel therapeutic vaccine called RUTI(R),in conjunction with an antibiotic. ... which reduces side effects and healthcare costs, by preventing,re-infection ...
Cached Biology Technology:DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 2DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 3DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 4EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 2EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 3Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 2Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 3
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... HOUSTON (Nov. 8, 2012) Four young scientists ... Research Institute (NSBRI). Through this two-year program, they conduct ... during long-duration spaceflights. In addition to receiving mentorship from ... are members of one of NSBRI,s seven research teams. ...
... in removing the extra copy of chromosome 21 in ... In Down syndrome, the body,s cells contain three ... A triplicate of any chromosome is a serious ... one-quarter of pregnancy loss from spontaneous miscarriages, according to ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... Officer, Chairman and President will present at the following conferences ... on Thursday, November 15, 2012 at 2:00 p.m. Mountain Time ... Jaffray Healthcare Conference on Tuesday, November 27 at 2:30 p.m. ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3Genomic Health to Present at Two Upcoming Investor Conferences 2Genomic Health to Present at Two Upcoming Investor Conferences 3
Recombinant Human Erythropoietin (Tissue Culture Grade)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Human PDGF R beta MAb (Clone # PR7212)...
Recombinant Mouse IL-23, CF...
Biology Products: